Search

Displaying results 1391 - 1400 of 10000 in total
  1. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    [L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800] … Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and

    Synonyms: 1-((3S)-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3, 4-d) pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one, 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-oneCategories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Varoglutamstat

    go.drugbank.com/drugs/DB18785
    Investigational

    Synonyms: 2-imidazolidinone, 1-(1h-benzimidazol-6-yl)-5-(4-propoxyphenyl)-, (5s)-, (5s)-1-(1h-benzimidazol-5-yl)-5-(4- propoxyphenyl)imidazolidin-2-one
  3. Drug

    Tirabrutinib

    go.drugbank.com/drugs/DB15227
    Investigational

    Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).

    Synonyms: 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-oneCategories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Rocbrutinib

    go.drugbank.com/drugs/DB19445
    Investigational

    Rocbrutinib is under investigation in clinical trial NCT05716087 (A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma).

    Synonyms: N-[5-[[6-[2-(1,3,4,6,7,8-Hexahydro-7,7-dimethyl-1-oxo-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-3-(hydroxymethyl)-4-pyridinyl]-3,4-dihydro-4-methyl-3-oxo-2-pyrazinyl]amino]-2-[(2S)-2-methyl-4-(tetrahydro, 2-Propenamide, N-[5-[[6-[2-(1,3,4,6,7,8-hexahydro-7,7-dimethyl-1-oxo-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-3-(hydroxymethyl)-4-pyridinyl]-3,4-dihydro-4-methyl-3-oxo-2-pyrazinyl]amino]-2-[(2S)-2
  5. Drug

    Stachyose

    go.drugbank.com/drugs/DB19276
    Experimental

    Synonyms: Gal(.alpha.1->6)gal(.alpha.1->6)glc(.alpha.1->2.beta.)fru, -d-glucopyranoside, .beta.-d-fructofuranosyl o-.alpha.-d-galactopyranosyl-(1->6)-o-.alpha.-d-galactopyranosyl-(1->6)-
  6. Drug

    BN104

    go.drugbank.com/drugs/DB18172
    Investigational

    Synonyms: (2-(6-(2-(4-cyclopropylpyrimidin-5-yl)-4-fluorophenoxy)-1,2,4-triazin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)((1S,3aR,6aS)-octahydrocyclopenta[c]pyrrol-1-yl)methanone
  7. Drug

    Ebvaciclib

    go.drugbank.com/drugs/DB18967
    Investigational

    Ebvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).

    Synonyms: 6-(difluoromethyl)-8-((1r,2r)-2-hydroxy-2-methylcyclopentyl)-2-((1- (methylsulfonyl)piperidin-4-yl) amino)pyrido(2,3-d)pyrimidin-7(8h)-one, Pyrido(2,3-d)pyrimidin-7(8h)-one, 6-(difluoromethyl)-8-((1r,2r)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)-4-piperidinyl)amino)-
  8. Drug

    Chlorpheniramine

    go.drugbank.com/drugs/DB01114
    ApprovedInvestigational

    A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications.

    Synonyms: γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine, γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamineMixtures: MAXİHOT 500 MG/4 MG/60 MG TEK KULLANIMLIK GRANÜL İÇEREN POŞET, 6 ADET, Sinu-C Suspension
  9. Drug

    4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Alpha-D-Lyxo-Hexopyranosyl-(1->4)-Alpha-D-Threo-Hexopyranosyl-(1->6)-Alpha-L-Threo-Hexopyranose

    go.drugbank.com/drugs/DB03495
    Experimental

    Synonyms: 4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Alpha-D-Lyxo-Hexopyranosyl-(1->4)-Alpha-D-Threo-Hexopyranosyl-(1->6)-Alpha-L-Threo-Hexopyranose
  10. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.

    Synonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates